Payment overview · 2025
General Payments
$395.98
21 reported records · 11 companies
Healthcare provider profile · identity verified
Sandip G Mehta, DO
Allopathic & Osteopathic Physicians|Internal Medicine · HURST, TX · NPI 1497770689
Verified facts
What the public records show
CMS Open Payments records show Sandip G Mehta, DO received $395.98 in general payments during 2025 across 21 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $78.91 | 19.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.80 | 16.6% | 3 | 2025 |
| Avvisto Therapeutics, LLC | Unresolved — no canonical attribution shown | $61.22 | 15.5% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $55.10 | 13.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $28.78 | 7.3% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $23.63 | 6.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.84 | 5.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.15 | 4.6% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $16.81 | 4.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.63 | 4.2% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $8.11 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $395.98 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $78.91 | 4 | 2025 |
Source payment records
|
|||||
| CYCLOSET Normalized: cycloset |
Drug | Avvisto Therapeutics, LLC | $61.22 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $55.10 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $44.25 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $28.78 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $8.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 317 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 310 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 307 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 228 | 65 |
| Montelukast Sodium | Montelukast Sodium | 198 | 61 |
| Furosemide | Furosemide | 179 | 58 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 172 | 24 |
| Lisinopril | Lisinopril | 166 | 55 |
| Metformin Hcl | Metformin Hcl | 155 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 151 | 52 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 117 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 38 |
| Losartan Potassium | Losartan Potassium | 105 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 100 | 29 |
| Omeprazole | Omeprazole | 95 | 28 |
| Trazodone Hcl | Trazodone Hcl | 89 | 29 |
| Potassium Chloride | Potassium Chloride | 88 | 29 |
| Carvedilol | Carvedilol | 84 | 28 |
| Gabapentin | Gabapentin | 84 | 28 |
| Simvastatin | Simvastatin | 82 | 26 |
| Eliquis | Apixaban | 77 | 20 |
| Propranolol Hcl | Propranolol Hcl | 70 | 23 |
| Glimepiride | Glimepiride | 69 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 20 |
| Atenolol | Atenolol | 64 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 64 | 20 |
| Alendronate Sodium | Alendronate Sodium | 61 | 20 |
| Methylprednisolone | Methylprednisolone | 58 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 22 |
| Ipratropium Bromide | Ipratropium Bromide | 54 | 19 |
| Celecoxib | Celecoxib | 53 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 52 | 19 |
| Spironolactone | Spironolactone | 52 | 17 |
| Allopurinol | Allopurinol | 51 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 15 |
| Donepezil Hcl | Donepezil Hcl | 49 | 18 |
| Clonidine Hcl | Clonidine Hcl | 48 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 11 |
| Tramadol Hcl | Tramadol Hcl | 44 | 11 |
| Fenofibrate | Fenofibrate | 39 | 14 |
| Buspirone Hcl | Buspirone Hcl | 38 | 14 |
| Sertraline Hcl | Sertraline Hcl | 38 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 36 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 12 |
| Metformin Hcl Er | Metformin Hcl | 34 | 15 |
| Meloxicam | Meloxicam | 33 | 11 |
| Rybelsus | Semaglutide | 33 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Jardiance | Empagliflozin | 29 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | 12 |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 19 |
| Prednisone | Prednisone | 21 | 11 |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Edarbi | Azilsartan Medoxomil | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $395.98 · 21 records | Bayer Healthcare Pharmaceuticals Inc. | ABRYSVO, AREXVY, CYCLOSET, Cologuard Collection Kit, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, Heplisav-B, JOURNAVX, Kerendia, PREVNAR 20, SHINGRIX, Veozah | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error